Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Thomas B. Davis"'
Autor:
Mingli Yang, Thomas B. Davis, Lance Pflieger, Michael V. Nebozhyn, Andrey Loboda, Heiman Wang, Michael J. Schell, Ramya Thota, W. Jack Pledger, Timothy J. Yeatman
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-21 (2022)
Abstract Background Over half of colorectal cancers (CRCs) are hard-wired to RAS/RAF/MEK/ERK pathway oncogenic signaling. However, the promise of targeted therapeutic inhibitors, has been tempered by disappointing clinical activity, likely due to com
Externí odkaz:
https://doaj.org/article/b3ce1c0168df4f64b92380ac36065a83
Autor:
Mingli Yang, Heiman Wang, Thomas B. Davis, Michael J. Schell, Angela P. Presson, Ramya Thota, Timothy J. Yeatman, Lance Pflieger, Malini Rajan, Warren Jack Pledger
Publikováno v:
Cancers, Vol 13, Iss 5394, p 5394 (2021)
Cancers
Volume 13
Issue 21
Cancers
Volume 13
Issue 21
Simple Summary Colorectal cancer (CRC) is a major cause of cancer deaths. Cetuximab is an FDA-approved, underutilized therapeutic targeting the epidermal growth factor receptor (EGFR) in metastatic CRC. To date, despite selection of patients with wil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea9c12a5fdf15cfd2f039db0bdf9c175
https://www.mdpi.com/2072-6694/13/21/5394
https://www.mdpi.com/2072-6694/13/21/5394
Autor:
Mingli Yang, Thomas B. Davis, Lance Pflieger, Michael V. Nebozhyn, Andrey Loboda, Heiman Wang, Michael J. Schell, Ramya Thota, W. Jack Pledger, Timothy J. Yeatman
Publikováno v:
BMC cancer. 22(1)
Background Over half of colorectal cancers (CRCs) are hard-wired to RAS/RAF/MEK/ERK pathway oncogenic signaling. However, the promise of targeted therapeutic inhibitors, has been tempered by disappointing clinical activity, likely due to complex resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b0e240acfc3977bad199d69a2f9f38b
https://pubmed.ncbi.nlm.nih.gov/35272617
https://pubmed.ncbi.nlm.nih.gov/35272617
Autor:
Mingli Yang, Heiman Wang, Thomas B. Davis, Lance Pflieger, Ramya Thota, W. Jack Pledger, Timothy J. Yeatman
Publikováno v:
Cancer Research. 82:5366-5366
EGFR inhibitor (EGFRi) therapies (cetuximab and panitumumab) have been approved for metastatic CRC patients who harbor wild-type KRAS/NRAS. Unfortunately, only ~50% of treated patients will respond to therapy. While FDA approved for first-line therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38eb068c42bf69916021af0c802b8db9
https://doi.org/10.1158/1538-7445.am2022-5366
https://doi.org/10.1158/1538-7445.am2022-5366
Autor:
Thomas B. Davis, Changgong Lee, W. Jack Pledger, Mingli Yang, Timothy J. Yeatman, Heiman Wang
Publikováno v:
Oncotarget
PTPRS is the most commonly mutated receptor tyrosine phosphatase in colorectal cancer (CRC). PTPRS has been shown to directly affect ERK and regulate its activation and nuclear localization. Here we identify that PTPRS may play a significant role in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44d7fabbb91b1d41139c409b69371508
https://pubmed.ncbi.nlm.nih.gov/31827720
https://pubmed.ncbi.nlm.nih.gov/31827720
Autor:
Mingli Yang, Thomas B. Davis, Lance Pflieger, Ramya Thota, Heiman Wang, Michael Nebozhyn, W. Jack Pledger, Andrey Loboda, Michael J. Schell, Timothy J. Yeatman
Publikováno v:
Cancer Research. 81:1083-1083
Colorectal cancers (CRCs) are hard-wired to RAS/RAF/MEK/ERK pathway oncogenic signaling. However, the promise of targeted therapeutic inhibitors (KRASi/BRAFi/MEKi/ERKi), has been tempered by disappointing clinical activity, likely due to complex resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7377471d11b8b12fe35d094d3e0aa890
https://doi.org/10.1158/1538-7445.am2021-1083
https://doi.org/10.1158/1538-7445.am2021-1083
Autor:
Mingli Yang, Timothy J. Yeatman, Michael J. Schell, Ramya Thota, Warren Jack Pledger, Thomas B. Davis
Publikováno v:
Journal of Clinical Oncology. 38:4094-4094
4094 Background: The Consensus Molecular Subtypes (CMS) of colorectal cancer (CRC) have prognostic and predictive value in identifying patients that derive benefit from EGFR targeted therapies. The CMS2 cohort was specifically noted to predict respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8689210b58370564c628102103324e3b
https://doi.org/10.1200/jco.2020.38.15_suppl.4094
https://doi.org/10.1200/jco.2020.38.15_suppl.4094
Autor:
Thomas B. Davis, Mingli Yang, Timothy J. Yeatman, Michael J. Schell, Heiman Wang, Le Ma, W. Jack Pledger
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-16 (2018)
Scientific Reports
Scientific Reports
Colorectal cancer (CRC) growth and progression is frequently driven by RAS pathway activation through upstream growth factor receptor activation or through mutational activation of KRAS or BRAF. Here we describe an additional mechanism by which the R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497dece94f89a3152b7e49d7bc6a98fc
https://doi.org/10.1038/s41598-018-27584-x
https://doi.org/10.1038/s41598-018-27584-x
Autor:
Heiman Wang, Mingli Yang, Le Ma, Timothy J. Yeatman, Michael J. Schell, Thomas B. Davis, W. Jack Pledger
Publikováno v:
Cancer Research. 77:4135-4135
The RAS pathway is a driver of many cancers, and has been targeted for the development of a variety of therapeutic inhibitors of BRAF, MEK, and more recently ERK. One of challenging issues is to predict response to targeted therapies. Here we report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95038f9489cdadc9981bc19a4ea0add6
https://doi.org/10.1158/1538-7445.am2017-4135
https://doi.org/10.1158/1538-7445.am2017-4135
Autor:
Thomas B. Davis
An essential, pocket-sized manual for industrial craftspeople from a brand relied on for more than a century The Audel™ Industrial Trades Multi-Craft Reference Manual is aimed at the industrial mechanic, millwright, machinist, plumber, pipefitter,
